TY - JOUR
T1 - β-Adrenergic Blockade for Survivors of Acute Myocardial Infarction
AU - Shalev, Oded
AU - Dror, Nili
AU - Rahav, Galia
AU - Eliakim, Rami
AU - Menczel, Jacob
AU - Altus, Philip
AU - Frishman, William H.
AU - Furberg, Curt D.
AU - Friedewald, William T.
PY - 1984/9/6
Y1 - 1984/9/6
N2 - To the Editor: In their review of β-adrenergic blockade for survivors of acute myocardial infarction (March 29 issue),1 Frishman et al. note that a large proportion of patients stand to benefit from βblockade therapy. In fact in the four placebo-controlled, randomized, double-blind clinical trials that provided population data,2 3 4 5 the proportion of survivors of acute myocardial infarction found eligible for this therapy was only 13 percent in the study by Hansteen et al., 23 percent in the β-blocker heart attack trial, 45 percent in the study by Julian et al., and 52 percent in the Norwegian timolol.
AB - To the Editor: In their review of β-adrenergic blockade for survivors of acute myocardial infarction (March 29 issue),1 Frishman et al. note that a large proportion of patients stand to benefit from βblockade therapy. In fact in the four placebo-controlled, randomized, double-blind clinical trials that provided population data,2 3 4 5 the proportion of survivors of acute myocardial infarction found eligible for this therapy was only 13 percent in the study by Hansteen et al., 23 percent in the β-blocker heart attack trial, 45 percent in the study by Julian et al., and 52 percent in the Norwegian timolol.
UR - http://www.scopus.com/inward/record.url?scp=0021227629&partnerID=8YFLogxK
U2 - 10.1056/NEJM198409063111012
DO - 10.1056/NEJM198409063111012
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???
C2 - 6147752
AN - SCOPUS:0021227629
SN - 0028-4793
VL - 311
SP - 670
EP - 671
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 10
ER -
